Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 5/20 | 0.70 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.70 |
| ▸ | CRHBP | P24387 | 1/20 | 0.70 |
| ▸ | MC4R | P32245 | 1/20 | 0.70 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.70 |
| ▸ | KEAP1 | Q14145 | 6/20 | 0.67 |
| ▸ | NFE2L2 | Q16236 | 6/20 | 0.67 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | RAB9A | P51151 | 4/20 | 0.53 |
| ▸ | NPC1 | O15118 | 3/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | ATM | Q13315 | 1/20 | 0.46 |
| ▸ | EIF4E | P06730 | 3/20 | 0.46 |
| ▸ | GUCY1A1 | Q02108 | 2/20 | 0.44 |
| ▸ | GUCY1B1 | Q02153 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3997788 | 0.92 | KEAP1 (0.65) | MEN1KMT2ACRHBPMC4RCRHR2 | |
| SCHEMBL3998254 | 0.87 | KEAP1 (0.67) | MEN1KMT2ACRHBPMC4RCRHR2 | |
| SCHEMBL4001247 | 0.86 | MEN1 (0.68) | MEN1KMT2ACRHBPMC4RCRHR2 | |
| SCHEMBL3992406 | 0.86 | KEAP1 (0.68) | MEN1KMT2ACRHBPMC4RCRHR2 | |
| SCHEMBL3994680 | 0.85 | GUCY1A1 (0.63) | MEN1KMT2ACRHBPMC4RCRHR2 | |
| SCHEMBL3994637 | 0.85 | KEAP1 (0.73) | MEN1KMT2ACRHBPMC4RCRHR2 | |
| SCHEMBL3995012 | 0.84 | KEAP1 (0.66) | MEN1KMT2ACRHBPMC4RCRHR2 | |
| SCHEMBL3994663 | 0.84 | KEAP1 (0.68) | MEN1KMT2ACRHBPMC4RCRHR2 | |
| SCHEMBL3997251 | 0.83 | KEAP1 (0.65) | MEN1KMT2ACRHBPMC4RCRHR2 | |
| SCHEMBL1197544 | 0.82 | MEN1 (1.00) | MEN1KMT2ACRHBPMC4RCRHR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3911675-A1 | METHODS TO DETERMINE WHETHER A SUBJECT IS SUITABLE OF BEING TREATED WITH AN AGONIST OF SOLUBLE GUANYLYL CYCLASE (SGC) | Bayer Aktiengesellschaft (DE) | 2021-11-24 | — | — | EP | claimed |
| WO-2020148379-A1 | METHODS TO DETERMINE WHETHER A SUBJECT IS SUITABLE OF BEING TREATED WITH AN AGONIST OF SOLUBLE GUANYLYL CYCLASE (SGC) | BAYER AKTIENGESELLSCHAFT (DE) | 2020-07-23 | — | — | WO | claimed |
| EP-2594270-A2 | The use of sGC stimulators, sGC activators, alone and combinations with PDE5 inhibitors for the treatment of systemic sclerosis (SSc) | BIP Patents (DE) | 2013-05-22 | — | — | EP | claimed |
| US-20220023246-A1 | STIMULATORS AND/OR ACTIVATORS OF SOLUBLE GUANYLATE CYCLASE (SGC) IN COMBINATION WITH AN INHIBITOR OF NEUTRAL ENDOPEPTIDASE (NEP INHIBITOR) AND/OR AN ANGIOTENSIN AII ANTAGONIST AND THE USE THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2022-01-27 | — | — | US | disclosed |
| EP-3911675-A1 | METHODS TO DETERMINE WHETHER A SUBJECT IS SUITABLE OF BEING TREATED WITH AN AGONIST OF SOLUBLE GUANYLYL CYCLASE (SGC) | Bayer Aktiengesellschaft (DE) | 2021-11-24 | — | — | EP | disclosed |
| US-11166932-B2 | Stimulators and/or activators of soluble guanylate cyclase (sGC) in combination with an inhibitor of neutral endopeptidase (NEP inhibitor) and/or an angiotensin AII antagonist and the use thereof | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2021-11-09 | — | — | US | disclosed |
| EP-3787610-A1 | THE USE OF SGC ACTIVATORS AND SGC STIMULATORS FOR THE TREATMENT OF COGNITIVE IMPAIRMENT | Bayer Aktiengesellschaft (DE) | 2021-03-10 | — | — | EP | disclosed |
| EP-3325013-B1 | STIMULATORS / ACTIVATORS OF SOLUBLE GUANYLAT CYCLASE IN COMBINATION WITH A NEP-INHIBITOR AND/OR AN ANGIOTENSIN AII-ANTAGONIST AND THE USE THEREOF | Bayer Pharma AG (DE) | 2020-09-23 | — | — | EP | disclosed |
| WO-2020148379-A1 | METHODS TO DETERMINE WHETHER A SUBJECT IS SUITABLE OF BEING TREATED WITH AN AGONIST OF SOLUBLE GUANYLYL CYCLASE (SGC) | BAYER AKTIENGESELLSCHAFT (DE) | 2020-07-23 | — | — | WO | disclosed |
| EP-3291811-B1 | THE USE OF SGC STIMULATORS, SGC ACTIVATORS, ALONE AND COMBINATIONS WITH PDE5 INHIBITORS FOR THE TREATMENT OF DIGITAL ULCERS (DU) CONCOMITANT TO SYSTEMIC SCLEROSIS (SSC) | Bayer Pharma AG (DE) | 2019-08-07 | — | — | EP | disclosed |
| US-20190125709-A1 | STIMULATORS AND/OR ACTIVATORS OF SOLUBLE GUANYLATE CYCLASE (SGC) IN COMBINATION WITH AN INHIBITOR OF NEUTRAL ENDOPEPTIDASE (NEP INHIBITOR) AND/OR AN ANGIOTENSIN AII ANTAGONIST AND THE USE THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2019-05-02 | — | — | US | disclosed |
| US-20130035340-A1 | sGC STIMULATORS OR sGC ACTIVATORS ALONE AND IN COMBINATION WITH PDE5 INHBITORS FOR THE TREATMENT OF CYSTIC FIBROSIS | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-02-07 | — | — | US | disclosed |
| US-20130035340-A1 | sGC STIMULATORS OR sGC ACTIVATORS ALONE AND IN COMBINATION WITH PDE5 INHBITORS FOR THE TREATMENT OF CYSTIC FIBROSIS | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-02-07 | — | — | US | disclosed |
| WO-2011161099-A1 | USE OF STIMULATORS AND ACTIVATORS OF SOLUBLE GUANYLATE CYCLASE FOR TREATING SICKLE-CELL ANEMIA AND CONSERVING BLOOD SUBSTITUTES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2011-12-29 | — | — | WO | disclosed |
| WO-2011147810-A1 | THE USE OF sGC STIMULATORS, sGC ACTIVATORS, ALONE AND COMBINATIONS WITH PDE5 INHIBITORS FOR THE TREATMENT OF SYSTEMIC SCLEROSIS (SSc). | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2011-12-01 | — | — | WO | disclosed |
| WO-2011147810-A1 | THE USE OF sGC STIMULATORS, sGC ACTIVATORS, ALONE AND COMBINATIONS WITH PDE5 INHIBITORS FOR THE TREATMENT OF SYSTEMIC SCLEROSIS (SSc). | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2011-12-01 | — | — | WO | disclosed |
| WO-2011095553-A1 | SGC STIMULATORS OR SGC ACTIVATORS IN COMBINATION WITH PDE5 INHBITORS FOR THE TREATMENT OF ERECTILE DYSFUNCTION | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-08-11 | — | — | WO | disclosed |
| WO-2011095553-A1 | SGC STIMULATORS OR SGC ACTIVATORS IN COMBINATION WITH PDE5 INHBITORS FOR THE TREATMENT OF ERECTILE DYSFUNCTION | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-08-11 | — | — | WO | disclosed |
| WO-2011095534-A1 | sGC STIMULATORS OR sGC ACTIVATORS ALONE AND IN COMBINATION WITH PDE5 INHBITORS FOR THE TREATMENT OF CYSTIC FIBROSIS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-08-11 | — | — | WO | disclosed |
| WO-2009068652-A1 | 2, 6-DISUBSTITUTED PYRIDINES AND 2, 4-DISUBSTITUTED PYRIMIDINES AS SOLUBLE GUANYLATE CYCLASE ACTIVATORS | SMITHKLINE BEECHAM CORPORATION (US) | 2009-06-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130035340-A1 | sGC STIMULATORS OR sGC ACTIVATORS ALONE AND IN COMBINATION WITH PDE5 INHBITORS FOR THE TREATMENT OF CYSTIC FIBROSIS | PDE5A, PDE3B, PDE3A | MEN1 4037/4885KMT2A 4107/4885CRHBP 1797/4885 |
| US-20190125709-A1 | STIMULATORS AND/OR ACTIVATORS OF SOLUBLE GUANYLATE CYCLASE (SGC) IN COMBINATION WITH AN INHIBITOR OF NEUTRAL ENDOPEPTIDASE (NEP INHIBITOR) AND/OR AN ANGIOTENSIN AII ANTAGONIST AND THE USE THEREOF | MME, ECE1, REN | MEN1 3303/4885KMT2A 4141/4885CRHBP 456/4885 |
| US-11166932-B2 | Stimulators and/or activators of soluble guanylate cyclase (sGC) in combination with an inhibitor of neutral endopeptidase (NEP inhibitor) and/or an angiotensin AII antagonist and the use thereof | MME, ECE1, REN | MEN1 3303/4885KMT2A 4141/4885CRHBP 456/4885 |
| US-20220023246-A1 | STIMULATORS AND/OR ACTIVATORS OF SOLUBLE GUANYLATE CYCLASE (SGC) IN COMBINATION WITH AN INHIBITOR OF NEUTRAL ENDOPEPTIDASE (NEP INHIBITOR) AND/OR AN ANGIOTENSIN AII ANTAGONIST AND THE USE THEREOF | MME, ECE1, REN | MEN1 3303/4885KMT2A 4141/4885CRHBP 456/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.